Watch Point Trust Co Has $293,000 Stake in Edwards Lifesciences Corp (NYSE:EW)

Watch Point Trust Co decreased its position in Edwards Lifesciences Corp (NYSE:EW) by 21.9% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,587 shares of the medical research company’s stock after selling 445 shares during the quarter. Watch Point Trust Co’s holdings in Edwards Lifesciences were worth $293,000 as of its most recent SEC filing.

Several other institutional investors have also recently bought and sold shares of the company. FTB Advisors Inc. acquired a new stake in Edwards Lifesciences during the first quarter worth approximately $25,000. TRUE Private Wealth Advisors acquired a new stake in Edwards Lifesciences during the second quarter worth approximately $26,000. Evolution Wealth Advisors LLC acquired a new stake in Edwards Lifesciences during the second quarter worth approximately $29,000. M&R Capital Management Inc. acquired a new stake in Edwards Lifesciences during the second quarter worth approximately $29,000. Finally, Field & Main Bank acquired a new stake in Edwards Lifesciences during the first quarter worth approximately $34,000. 82.43% of the stock is currently owned by institutional investors.

In other news, VP Donald E. Bobo, Jr. sold 5,369 shares of the stock in a transaction on Friday, May 17th. The stock was sold at an average price of $175.06, for a total value of $939,897.14. Following the completion of the transaction, the vice president now directly owns 26,043 shares in the company, valued at approximately $4,559,087.58. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, VP Huimin Wang sold 4,650 shares of the stock in a transaction on Monday, August 5th. The shares were sold at an average price of $211.54, for a total value of $983,661.00. Following the completion of the transaction, the vice president now owns 36,898 shares of the company’s stock, valued at $7,805,402.92. The disclosure for this sale can be found here. Insiders sold a total of 142,948 shares of company stock valued at $27,936,332 over the last quarter. 1.63% of the stock is owned by corporate insiders.

A number of equities research analysts recently issued reports on the company. Raymond James increased their price target on Edwards Lifesciences from $200.00 to $232.00 and gave the stock an “outperform” rating in a research report on Wednesday, July 24th. Credit Suisse Group increased their price target on Edwards Lifesciences from $221.00 to $226.00 and gave the stock an “outperform” rating in a research report on Wednesday, July 24th. Deutsche Bank increased their price target on Edwards Lifesciences from $164.00 to $184.00 and gave the stock a “hold” rating in a research report on Wednesday, April 24th. Morgan Stanley increased their price target on Edwards Lifesciences from $210.00 to $228.00 and gave the stock an “overweight” rating in a research report on Wednesday, July 24th. Finally, Zacks Investment Research raised Edwards Lifesciences from a “hold” rating to a “buy” rating and set a $232.00 price target on the stock in a research report on Thursday, July 25th. Two research analysts have rated the stock with a sell rating, six have assigned a hold rating and fourteen have issued a buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $204.74.

NYSE EW traded up $3.30 on Thursday, hitting $216.81. 25,008 shares of the company’s stock were exchanged, compared to its average volume of 1,186,828. The business has a 50-day moving average price of $200.64. The company has a current ratio of 3.38, a quick ratio of 2.48 and a debt-to-equity ratio of 0.18. Edwards Lifesciences Corp has a 52 week low of $134.53 and a 52 week high of $219.71. The company has a market cap of $44.90 billion, a PE ratio of 45.96, a price-to-earnings-growth ratio of 2.72 and a beta of 0.87.

Edwards Lifesciences (NYSE:EW) last released its earnings results on Tuesday, July 23rd. The medical research company reported $1.38 earnings per share for the quarter, topping the consensus estimate of $1.33 by $0.05. Edwards Lifesciences had a return on equity of 31.25% and a net margin of 18.29%. The firm had revenue of $1.09 billion during the quarter, compared to analysts’ expectations of $1.04 billion. During the same period in the prior year, the company earned $1.24 earnings per share. The company’s quarterly revenue was up 15.2% on a year-over-year basis. On average, equities research analysts anticipate that Edwards Lifesciences Corp will post 5.34 EPS for the current year.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States and internationally. It offers transcatheter heart valve therapy products comprising transcatheter aortic valve replacement, and transcatheter mitral and tricuspid therapies for the nonsurgical replacement of heart valves.

Featured Article: What is Cost of Goods Sold (COGS)?

Institutional Ownership by Quarter for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit